Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Here's How Pfizer Gained 20.5% in 2018

Motley Fool Tuesday, 15 January 2019
While its industry was getting crushed, this big pharma surged forward.
0
shares
ShareTweetSavePostSend
 
Credit: The Street - Published < > Embed
News video: Takeda Pharmaceutical CEO Talks Big Pharma Trends

▶ Takeda Pharmaceutical CEO Talks Big Pharma Trends 03:01

Big pharmaceutical companies have begun 2019 with a bang. Blockbuster deals like Bristol Myers Squibb's $74 billion deal for Celgene , Eli Lilly's $8 billion deal for Loxo Oncology, and Takeda Pharmaceutical's $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is...

You Might Like


Recent related videos from verified sources

Trade Deal Wall Street Hopes Muted By Growth Fears [Video]Trade Deal Wall Street Hopes Muted By Growth Fears

NEW YORK (Reuters) - Wall Street languished near the starting gate in mid-afternoon trading on Monday as investor hopes over U.S.-China trade talks were muted by concerns about possible congressional..

Credit: Wochit Business     Duration: 00:32Published

Pfizer approaches AstraZeneca [Video]Pfizer approaches AstraZeneca

Pfizer confirmed its interest in a takeover of the UK pharmaceuticals group, in what would be one of the biggest deals in the industry's history. Lex's Oliver Ralph and Robert Armstrong discuss the..

Credit: Financial Times     Duration: 03:21Published

Dow Movers: PFE, AAPL [Video]Dow Movers: PFE, AAPL

In early trading on Monday, shares of Apple (AAPL) topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.6%. Year to date, Apple registers a 7.3% gain.

Credit: Market News Video     Duration: 01:02Published

Pfizer deal, Turkey downs Russian jet | FirstFT [Video]Pfizer deal, Turkey downs Russian jet | FirstFT

► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs Josh de la Mare provides Tuesday’s top stories, with Pfizer seeking support from Washington for its $160bn Allergan deal,..

Credit: Financial Times     Duration: 01:08Published

Dow Movers: DWDP, PFE [Video]Dow Movers: DWDP, PFE

In early trading on Thursday, shares of Pfizer topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.9%. Year to date, Pfizer has lost about 3.7% of its..

Credit: Market News Video     Duration: 01:02Published

What Boeing's Report Means for U.S. Companies With China Exposure [Video]What Boeing's Report Means for U.S. Companies With China Exposure

Boeing smashed Wall Street expectations Wednesday, Jan. 30. The company is Real Money's stock of the day. The company said earnings for the three months ending in December came in at $5.48 per share, a..

Credit: The Street     Duration: 02:39Published

Dow Movers: PFE, INTC [Video]Dow Movers: PFE, INTC

In early trading on Thursday, shares of Intel Corp (INTC) topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.9%. Year to date, Intel Corp registers a..

Credit: Market News Video     Duration: 01:02Published

Dow Movers: PFE, BA [Video]Dow Movers: PFE, BA

In early trading on Thursday, shares of Boeing (BA) topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.1%. Year to date, Boeing registers a 6.8% gain.

Credit: Market News Video     Duration: 01:02Published

'The Volatility Will Be With Us for a While,' Says NYSE Trader [Video]'The Volatility Will Be With Us for a While,' Says NYSE Trader

What should investors watch in the markets? Tim Anderson, managing director at TJM Investments, spoke to TheStreet about the markets, oil and what he expects from earnings season. Is the Government..

Credit: The Street     Duration: 11:42Published

Major Pharma Companies Are Reportedly Hiking Drug Prices In 2019 [Video]Major Pharma Companies Are Reportedly Hiking Drug Prices In 2019

Allergan and Pfizer have confirmed price hikes, and an expert told the Wall Street Journal more drugmakers may follow suit.

Credit: Rumble     Duration: 00:51Published


Recent related news from verified sources

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and...
Reuters India Also reported by •RTE.ieReutersSeekingAlpha

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a...
Reuters Also reported by •SeekingAlpha

FDA accepts Pfizer's marketing application for Bavencio + Inlyta for RCC


SeekingAlpha

Better Buy: Gilead Sciences vs. Pfizer

Which of these drugmakers will push your portfolio higher in the years ahead?
Motley Fool


Tweets about this


Other recent news in Markets

FOMC MINUTES: Lot of useful information – Danske BankNew SAMSUNG Galaxy S10 Includes Cryptocurrency Key Storage
MARK ZUCKERBERG Considers Blockchain Authorization of Data in Recent InterviewBlockchain in HEALTH INSURANCE: More Accuracy, More Transparency and More Efficiency
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest